SCHEMBL3344845

SCHEMBL3344845

c1coc(-c2ccc3ccccc3n2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.55
ALDH1A1 P00352 8/20 0.55
HSD17B10 Q99714 8/20 0.55
MEN1 O00255 7/20 0.55
MAPT P10636 7/20 0.55
KMT2A Q03164 7/20 0.55
TDP1 Q9NUW8 6/20 0.55
HPGD P15428 6/20 0.55
POLB P06746 5/20 0.55
L3MBTL1 Q9Y468 5/20 0.55
PKM P14618 5/20 0.55
RECQL P46063 4/20 0.55
BLM P54132 4/20 0.55
ALOX15 P16050 3/20 0.55
CASP1 P29466 2/20 0.55
PTPN7 P35236 2/20 0.55
CASP7 P55210 2/20 0.55
TSHR P16473 2/20 0.55
DCTPP1 Q9H773 1/20 0.53
TP53 P04637 4/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23954159 0.78 ALDH1A1 (0.52) KDM4EALDH1A1HSD17B10MEN1MAPT
Iodide SCHEMBL4392302 0.77 RAB9A (0.59) KDM4EALDH1A1HSD17B10MEN1MAPT
SCHEMBL170196 0.76 RAB9A (0.64) KDM4EALDH1A1HSD17B10MEN1MAPT
SCHEMBL29374931 0.76 RAB9A (0.64) KDM4EALDH1A1HSD17B10MEN1MAPT
SCHEMBL29180363 0.76 KDM4E (0.58) KDM4EALDH1A1HSD17B10MEN1MAPT
SCHEMBL3060017 0.74 KDM4E (0.58) KDM4EALDH1A1HSD17B10MEN1MAPT
SCHEMBL29746310 0.74 CYP11B1 (0.53) KDM4EALDH1A1HSD17B10MEN1MAPT
SCHEMBL3647009 0.74 CYP11B1 (0.53) KDM4EALDH1A1HSD17B10MEN1MAPT
SCHEMBL34463709 0.74 RAB9A (0.61) KDM4EALDH1A1HSD17B10MEN1MAPT
SCHEMBL10866984 0.74 RAB9A (0.61) KDM4EALDH1A1HSD17B10MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111471009-A Preparation method and application of 2-arylquinoline derivative 安阳师范学院 2020-07-31 CN claimed
CN-105801478-B A kind of method that 2- aryl quinolines are prepared by cyclo other compounds 常州大学 2018-05-25 CN claimed
JP-61277675-A None JP disclosed
EP-4330233-A1 PHENYL -O-QUINOLINE, QUINAZOLINE, THIENOPYRIDINE, THIENOPYRIMIDINE, PYRROLOPYRIDINE, PYRROLOPYRIMIDINE COMPOUNDS HAVING ANTICANCER ACTIVITY Chengdu Anticancer Bioscience, Ltd. (CN) 2024-03-06 EP disclosed
CN-111471009-A Preparation method and application of 2-arylquinoline derivative 安阳师范学院 2020-07-31 CN disclosed
CN-105801478-B A kind of method that 2- aryl quinolines are prepared by cyclo other compounds 常州大学 2018-05-25 CN disclosed
CN-105801478-A Method for preparing 2-aryl quinoline by cyclic ether compound 常州大学 2016-07-27 CN disclosed
WO-2015106272-A1 SMALL MOLECULE INHIBITORS OF APOBEC3G AND APOBEC3B HARKI DANIEL A (US) 2015-07-16 WO disclosed
WO-2015040424-A1 TETRAHYDROISOQUINOLINE COMPOUNDS AND THEIR USE AS PYRUVATE DEHYDROGENASE KINASE INHIBITORS VERNALIS (R&D) LIMITED (GB) 2015-03-26 WO disclosed
WO-2008154207-A9 METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2010-04-22 WO disclosed
US-20090118135-A1 METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS THE BURNHAM INSTITUTE (US) 2009-05-07 US disclosed
US-20090069301-A1 Acridine and Quinoline Derivatives as Sirtuin Modulators SIRTRIS PHARMACEUTICALS, INC. (US) 2009-03-12 US disclosed
WO-2008154207-A1 METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2008-12-18 WO disclosed
EP-1856099-A2 ACRIDINE AND QUINOLINE DERIVATIVES AS SIRTUIN MODULATORS Sirtris Pharmaceuticals, Inc. (US) 2007-11-21 EP disclosed
WO-2006094237-A2 ACRIDINE AND QUINOLINE DERVATIVES AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2006-09-08 WO disclosed
JP-S61277675-A 2-QUINOYLFURAN DERIVATIVE MITSUI PETROCHEM IND LTD 1986-12-08 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118135-A1 METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS BCL2, BAX, BAD KDM4E 3373/4885ALDH1A1 3724/4885HSD17B10 2065/4885
US-20090069301-A1 Acridine and Quinoline Derivatives as Sirtuin Modulators SIRT1, SIRT3, SIRT2 KDM4E 2555/4885ALDH1A1 1461/4885HSD17B10 3123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.